Roughly two years after initiating an investigation into pharmacy benefit managers (PBMs), the Federal Trade Commission (FTC) has unveiled its interim report, casting a critical spotlight on these prescription drug intermediaries. According to the FTC’s findings, the PBM market’s high concentration has facilitated enormous profits for these companies while creating a challenging environment for patients and independent pharmacies.
The report singles out the six largest PBMs—CVS Caremark, Express Scripts, Optum Rx, Humana Pharmacy Solutions, MedImpact, and Prime Therapeutics—who collectively manage 95% of all U.S. prescriptions.
FTC Chair Lina M. Khan emphasized that dominant PBMs can inflate drug costs, specifically overcharging for essential medications like cancer drugs. The report also highlights how these PBMs can disadvantage independent pharmacies, a point of concern for many Americans, particularly those in rural areas. Khan noted the FTC’s commitment to continued scrutiny of dominant players in healthcare markets.
Following the report, some news outlets, including the Wall Street Journal, reported that the FTC is preparing to sue CVS Caremark, Express Scripts, and Optum Rx over issues related to insulin prices and rebate negotiations. However, the FTC declined to provide comments on this potential legal action.
It’s worth noting that the release of the interim report was not unanimous; Commissioner Melissa Holyoak dissented, critiquing the report for lacking economic rigor and adequate examination of how PBM practices affect consumer prices. Her dissenting statement underscores these concerns.
Several stakeholders, including Juliette Cubanski of the Program on Medicare Policy at KFF, suggest the report could catalyze legislative action to promote transparency in the sector. Bills such as the Pharmacy Benefit Manager Transparency Act and the Modernizing and Ensuring PBM Accountability Act have garnered bipartisan support and aim to regulate PBM practices further.
The report dissects the evolution of PBMs since their inception in the 1960s and points to significant consolidation in the space, with the top three PBMs processing approximately 80% of U.S. prescriptions as of 2023. Independent pharmacies, particularly in rural America, face increasing financial challenges, contributing to the closure of about 10% of these pharmacies between 2013 and 2022.
PBMs have criticized the FTC’s interim report. The Pharmaceutical Care Management Association (PCMA) lambasted the report for relying on anecdotes and comments from anonymous, self-interested parties. PBM representatives, including those from Optum Rx and CVS Caremark, argued that the report’s conclusions are flawed and overlook the value PBMs bring to the healthcare system.
The confrontation between PBMs and pharmaceutical companies continues, with both sides blaming each other for rising drug costs. Legislative reforms targeting both sectors appear imminent, driven by bipartisan support, leaving stakeholders to hope that meaningful changes will soon materialize.
For more details, you can read the full article here.